<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100112</url>
  </required_header>
  <id_info>
    <org_study_id>CB-01-02/06</org_study_id>
    <nct_id>NCT01100112</nct_id>
  </id_info>
  <brief_title>(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets</brief_title>
  <official_title>Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg
      Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are
      not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01
      (parent study [NCT00679432]).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete the parent study and who do not achieve clinical remission will be
      eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy
      the entry criteria for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients Achieving Clinical Remission</measure>
    <time_frame>At the end of the 8 week treatment period</time_frame>
    <description>The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of &lt; or = 1 with a score of 0 for both rectal bleeding and stool frequency, and &gt; or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance).
The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum [worst] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = &gt; 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Efficacy Endpoint is Clinical Improvement</measure>
    <time_frame>After 8 weeks treatment period</time_frame>
    <description>The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of &gt; or = 3 points from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.</measure>
    <time_frame>Throughout the 8 week treatment period</time_frame>
    <description>Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8.
The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide-MMX 9 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
    <arm_group_label>Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 to 74 years of age, who are able to understand and
             voluntarily provide written informed consent

          -  Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are not
             in clinical remission

          -  Diagnosis of ulcerative colitis of mild to moderate severity with an Ulcerative
             Colitis Disease Activity Index (UCDAI) &lt;or= 10 according to Sutherland

          -  Females of child-bearing potential must have had a serum pregnancy test performed at
             the Final Visit of the parent study, and must use an acceptable contraceptive method
             throughout the treatment period. Female subjects must also not be actively
             breast-feeding through the entire study period.

          -  Ability to comprehend the full nature and purpose of the study, including possible
             risks and side effects

          -  Ability to co-operate with the investigator and to comply with the requirements of the
             entire study

        Exclusion Criteria:

          -  Did not complete study CB-01-02/01

          -  Achieved clinical remission in study CB-01-02/01

          -  Patients with severe ulcerative colitis (UCDAI &gt;10)

          -  Patients with infectious colitis

          -  Evidence or history of toxic megacolon

          -  Severe anemia, leucopenia, or granulocytopenia

          -  Use of immunosuppressive agents in the last 8 weeks before the study

          -  use of anti-tumor necrosis factor alpha agents in the last three months

          -  Concomitant use of any rectal preparation for the treatment of ulcerative colitis

          -  Concomitant use of antibiotics

          -  Concurrent use of cytochrome P-450 3A4 (CYP3A4) inducers and CYP3A4 inhibitors.

          -  Patients with verified, presumed of expected pregnancy or ongoing lactation

          -  Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency
             and/or severe impairment of the bio-humoral parameters (i.e., 2x upper limit of normal
             for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl
             transpeptidase, or creatinine)

          -  Patients with severe disease(s) in other organs of systems

          -  Patients with local of systemic complications of other pathological states requiring a
             therapy with corticosteroids and/or immunosuppressive agents

          -  Patients diagnosed with Type 1 diabetes

          -  Patients diagnosed with or with a family history of glaucoma

          -  Patients with known hepatitis B, hepatitis C, or with human immunodeficiency virus
             (HIV), according to the local privacy policy

          -  Any other medical condition that in the principal investigator's opinion would make
             the administration of the study drug or study procedures hazardous to the subject or
             obscure the interpretation of adverse events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9001</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9009</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9012</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9016</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9006</name>
      <address>
        <city>Assam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9007</name>
      <address>
        <city>Gujarat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9004</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9015</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9003</name>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9002</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9008</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9013</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9018</name>
      <address>
        <city>Rajasthan</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9005</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9014</name>
      <address>
        <city>Uttar Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <disposition_first_submitted>February 9, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 13, 2012</disposition_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>Budesonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from February 2010 to July 2010</recruitment_details>
      <pre_assignment_details>Patient had to have failed to achieve clinical remission in parent study CB-01-02/01. One of the 61 enrolled patients did not receive study drug. Therefore, 60 patients were evaluable for safety and efficacy analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Budesonide</title>
          <description>Budesonide-multi-matrix system (MMX) 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received at least 1 dose of study drug were considered Evaluable patients. Total evaluable population was 60.</population>
      <group_list>
        <group group_id="B1">
          <title>Budesonide</title>
          <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients Achieving Clinical Remission</title>
        <description>The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of &lt; or = 1 with a score of 0 for both rectal bleeding and stool frequency, and &gt; or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance).
The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum [worst] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = &gt; 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
        <time_frame>At the end of the 8 week treatment period</time_frame>
        <population>All patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Achieving Clinical Remission</title>
          <description>The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of &lt; or = 1 with a score of 0 for both rectal bleeding and stool frequency, and &gt; or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance).
The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum [worst] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = &gt; 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
          <population>All patients who received at least 1 dose of study drug.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Efficacy Endpoint is Clinical Improvement</title>
        <description>The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of &gt; or = 3 points from baseline.</description>
        <time_frame>After 8 weeks treatment period</time_frame>
        <population>All patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Secondary Efficacy Endpoint is Clinical Improvement</title>
          <description>The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of &gt; or = 3 points from baseline.</description>
          <population>All patients who received at least 1 dose of study drug.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.</title>
        <description>Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.</description>
        <time_frame>Throughout the 8 week treatment period</time_frame>
        <population>All patients who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.</title>
          <description>Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.</description>
          <population>All patients who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other non-serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Improvement</title>
        <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8.
The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
        <time_frame>8 weeks</time_frame>
        <population>All patients who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Improvement</title>
          <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8.
The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.</description>
          <population>All patients who received at least one dose of study drug.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 day Â± 2 day (study duration) + 30 day safety followup period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Budesonide</title>
          <description>Budesonide-MMX 9 mg tablet
Budesonide : One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an open label study. There was no reference therapy for statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Huang, MD, Senior Medical Director, Clinical Research</name_or_title>
      <organization>Santarus, Inc.</organization>
      <phone>8583145700</phone>
      <email>contact@santarus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

